Roivant Sciences (NASDAQ:ROIV – Get Free Report) is anticipated to issue its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.2881) per share and revenue of $1.9970 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.
Roivant Sciences Price Performance
ROIV stock traded up $0.89 during midday trading on Tuesday, reaching $34.20. The company had a trading volume of 808,856 shares, compared to its average volume of 5,892,207. Roivant Sciences has a 1 year low of $10.90 and a 1 year high of $37.00. The company has a market capitalization of $24.60 billion, a P/E ratio of -56.93 and a beta of 1.12. The firm has a 50-day moving average price of $32.70 and a 200-day moving average price of $29.17.
Analyst Ratings Changes
A number of analysts have recently issued reports on ROIV shares. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Leerink Partners set a $42.00 price target on Roivant Sciences in a research report on Thursday, May 21st. Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a research note on Friday. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, TD Cowen increased their price objective on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.59.
Insider Buying and Selling at Roivant Sciences
In other news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the transaction, the director directly owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 12,380 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the transaction, the director directly owned 13,689,166 shares in the company, valued at $482,953,776.48. This trade represents a 0.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 2,055,913 shares of company stock worth $69,639,633 over the last three months. Company insiders own 8.80% of the company’s stock.
Hedge Funds Weigh In On Roivant Sciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP boosted its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Kestra Advisory Services LLC purchased a new position in shares of Roivant Sciences in the fourth quarter worth $47,000. CIBC Private Wealth Group LLC increased its stake in shares of Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after buying an additional 2,665 shares during the period. Osaic Holdings Inc. raised its holdings in Roivant Sciences by 204.2% during the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after buying an additional 3,882 shares during the last quarter. Finally, GeoWealth Management LLC bought a new stake in Roivant Sciences during the 4th quarter valued at $73,000. 64.76% of the stock is currently owned by institutional investors.
Roivant Sciences Company Profile
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.
Featured Stories
- Five stocks we like better than Roivant Sciences
- The AI Chip Stock Making a Quiet Move Toward Dominance
- Why Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps
- Dodging Deutsche Telekom: T-Mobile’s Strategic Win
- GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
